Peritoneal metastases of rare carcinomas treated with cytoreductive surgery and HIPEC - A single center case series
Open Access
- 9 August 2017
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Medicine & Surgery
- Vol. 22, 7-11
- https://doi.org/10.1016/j.amsu.2017.08.009
Abstract
Introduction: In selected cases, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is an established treatment for patients suffering from peritoneal metastases from colorectal, ovarian, gastric or appendiceal origin. The effectiveness of this extensive has not been elucidated within other rare diseases by now. Methods: We conducted a retrospective analysis of patients treated with CRS for peritoneal carcinomatosis during the period between July 2010 and September 2015. Exclusion criteria were adenocarcinomas of the stomach, colon, neoplasms of the appendix, mesothelioma and ovarian cancers. Aim of this study was to examine the feasibility, complication rate and survival of patients with rare diseases. Results: A total of 14 Patients were included: Four rare gynecological tumors, three adenocarcinomas of the small intestine, three retroperitoneal sarcomas, one cholangiocellular carcinoma, one neuroendocrine gastric tumor, one malignant peripheral nerve sheath tumor and one cancer of unknown primary syndrome. In 12 of 14 patients a macroscopically complete tumorresection could be achieved. No patient died during hospitalization. Seven of 14 patients experienced general complication of grade III according to NCI CTCAE V4.0, while two experienced complications of grade IV. Median follow-up and one year overall survival were 15.5 months and 46.8%, respectively. Conclusion: For patients with rare tumors, CRS and HIPEC is feasible with an acceptable perioperative morbidity and mortality. To improve knowledge in patient selection and outcome, rare tumors treated with CRS and HIPEC should be documented in central databases (as for example BIG RENAPE, Pierre-Benite, France).This publication has 34 references indexed in Scilit:
- Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal ChemotherapyJournal of Clinical Oncology, 2012
- Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancerEuropean Journal of Surgical Oncology, 2011
- Systematic Review on the Efficacy of Multimodal Treatment of Sarcomatosis with Cytoreduction and Intraperitoneal ChemotherapyAnnals of Surgical Oncology, 2010
- A Comparative Study of Complete Cytoreductive Surgery Plus Intraperitoneal Chemotherapy to Treat Peritoneal Dissemination From Colon, Rectum, Small Bowel, and Nonpseudomyxoma AppendixAnnals of Surgery, 2010
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional ExperienceJournal of Clinical Oncology, 2009
- Cytoreduction and intraperitoneal heated chemotherapy for the treatment of endometrial carcinoma recurrent within the peritoneal cavityInternational Journal of Gynecologic Cancer, 2007
- Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II TrialJournal of Clinical Oncology, 2005
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- Mucinous adenocarcinoma of the small bowel with peritoneal seedingEuropean Journal of Surgical Oncology, 2002
- Salvage surgery for patients with recurrent gastrointestinal sarcomaCancer, 2000